FDA Grants Orphan Drug Designation to TP-1287 for Ewing Sarcoma
The FDA has granted an orphan drug designation to TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma.
Source: onclive.com
Stay updated with breaking news from Tp 1287. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted an orphan drug designation to TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma.